tbuckley/cabot-search huggingface dataset:
Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients
Authors: Nicolaus Kröger, Evgeny Klyuchnikov, Thomas Stübig, Christine Wolschke, Francis Ayuk, Tatjana Zabelina, York Hildebrandt, Ulrike Bacher, Anita Badbaran, Georgia Schilling, Orhan Sezer, Djordje Atanackovic, Martin Kropff, Axel R. Zander
Journal: Blood (2011)
OP0292 Interspinous Bursitis Evaluation by Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica Extension Study
Authors: K. Kume, K. Amano, S. Yamada, T. Kanazawa, K. Hatta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Polymyalgia rheumatica (PMR) is a common inflammatory disease of the elderly, and 2012 provisional classification criteria were suggested, however it is provisional and not meant for diagnosis purpose<sup>1)</sup>. Ultrasound (US), MRI and other modalities were often detected interspinous bursitis in patients with PMR<sup>2)</sup>. To develop 2012 provisional classification criteria, adding interspinous bursitis evaluation by US. We reported the usefulness of interspinous bursitis evaluation by US at 2015 American college of rheumatology annual meeting. <h3>Objectives</h3> In this time, we compared 2012 provisonal classification criteria to adding interspinous bursitis evaluation by US, and checked the association between US evaluation of conventional (shoulder and hip) bursitis and interspinous bursitis. <h3>Methods</h3> This is a prospective cohort study. Candidate criteria were evaluated 161 patients with new onset untreated PMR, and 174 patients non-PMR comparison subjects with conditions mimicking PMR. We compared the diagnosis ability of 2012 provisional classification criteria with 2012 provisional classification criteria, adding interspinous bursitis evaluation by US. US evaluation was checked cervical and lumbar spine added conventional shoulder and hip. In PMR patients, we evaluated the prevalance of interspinous bursitis without hip or shoulder bursitis, the association between interspinous bursitis and shoulder or hip bursitis. <h3>Results</h3> 2012 provisional classification criteria scoring system had 66% sensitivity and 82% specificity. Adding interspinous bursitis by US had significantly increased sensitivity to 89%,and not significantly decreased specificity to 77%.(ROC anaylysis: p&lt;0.05) PMR patients without hip or shoulder bursitis were 56 patients. Surprisingly, PMR patients without hip or shoulder bursitis had interspinous bursitis with high prevalence. (85%, 48 patients) No correlation was found between interspinous bursitis and shoulder or hip bursitis (r=0.09, <i>P</i>=0.36). <h3>Conclusions</h3> Interspinous bursitis by US is important evalution in patients with PMR. Interspinous bursitis by US should be added classification criteria for PMR. If patients were suspected of PMR, interspinous bursitis by US might be performed despite hip and shoulder bursitis. <h3>References</h3> Dasgupta B, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 Apr;71(4):484–92. doi: 10.1136/annrheumdis-2011-200329. Camellino D, et al. Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain. Arthritis Res Ther. 2014 Dec 1;16(6):492. [Epub ahead of print] <h3>Disclosure of Interest</h3> None declared
Galectin-9 Overcomes Various Types of Treatment Resistance through ATF-3/Noxa Pathway-Mediated Apoptosis In Chronic Myelogenous Leukemia
Authors: Junya Kuroda, Mio Yamamoto, Hisao Nagoshi, Tsutomu Kobayashi, Nasa Sasaki, Yuji Shimura, Shigeo Horiike, Shinya Kimura, Mitsuomi Hirashima, Masafumi Taniwaki
Journal: Blood (2010)
Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer—Reply
Authors: Aaron D. Falchook, Ramsankar Basak, Ronald C. Chen
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.
Authors: Siegfried Janz, Brian G Van Ness, Vishala Neppalli, Ray Liu, Michael D Pickard, Jennifer Terkelsen, Daniel Bradley, Ling Hu, Erik Kupperman, Mark Manfredi, Edmund Lee
Journal: Blood (2009)
The Promise of Palliative Care
Authors: Preeti N. Malani, Eric Widera
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Black cohosh extracts: a potential phytoestrogen for treatment of menopausal symptoms
Authors: Weizhu Zhu, Wenyi Qin, Jennifer Haubner, Edward Sauter
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

5188 

Background: Menopausal symptoms are a serious health problem in postmenopausal women. Hormone replacement therapy (HRT) is prescribed to ameliorate menopausal symptoms, but has been associated with an increased risk of developing breast cancer. Natural estrogens (phytoestrogens) present in a variety of plants are thought to be safer than synthetic estrogen for the treatment of menopausal symptoms. Black cohosh extract (BCE), the largest selling dietary supplement in the U.S. used to treat menopausal symptoms, is claimed to be effective but its mechanism of action is unclear. The purpose of this study was to determine if BCE administered to symptomatic postmenopausal women would 1) alleviate menopausal symptoms and 2) act in an estrogenic fashion to stimulate the breast as measured by changes in nipple aspirate fluid (NAF) and serum levels of estradiol (E2) and the estrogen regulated protein (pS2). Methods and Materials: 19 Postmenopausal women were enrolled in the study. Patients took a capsule containing 40 mg of BCE twice daily for 12 weeks, followed by a 12 week washout period. The Kupperman Menopausal Index (KMI) was used to grade menopausal symptoms before BCE intervention and at 4, 12, 24 weeks. NAF and blood specimen collections were performed at 0, 4, 12, 24 weeks. E2 and pS2 levels in NAF and serum were measured using commercially available radioimmunoassays. Results were calculated after controlling for total NAF protein. Results and Conclusion: KMI scores significantly declined (p<0.001) at both 4 and 12 wks after starting BCE, and partially rebounded by 24 wks. Median baseline values for NAF E2 and pS2 in NAF were 261pg/ml and 1.55μg/g, which did not significantly change after BCE. The results of this investigation suggest that BCE is effective in relieving menopausal symptoms, and does not cause estrogen stimulation in the breasts of postmenopausal women at the dose ingested, suggesting that BCE may be a safe alternative to HRT for women with menopausal symptoms.
Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival.
Authors: Mats L. Brune, Jacob M. Rowe, Jeff Szer, Donna E. Hogge, John Catalano, Elisabeth Wallhult, Bo I. Nilsson, Bengt Simonsson, Ruth Spearing, Stephane Allard, Edward A. Stadtmauer, Kristoffer Hellstrand
Journal: Blood (2007)
Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.
Authors: Bing Chen, Wei-Li Zhao, Jie Jin, Yong-Quan Xue, Xin Cheng, Xiao-Ting Chen, Jing Cui, Zhi-Mei Chen, Qi Cao, Guang Yang, Ying Yao, Jian-Hua Tong, Jun-Min Li, Jue Chen, Shu-Min Xiong, Zhi-Xiang Shen, Zhu Chen, Sai-Juan Chen
Journal: Blood (2004)
Detection of Novel Pathogenic Gene Rearrangements in Pediatric Acute Myeloid Leukemia By RNA Sequencing
Authors: Norio Shiba, Kenichi Yoshida, Yuichi Shiraishi, Yusuke Hara, Genki Yamato, Taeko Kaburaki, Masashi Sanada, Kentaro Oki, Daisuke Tomizawa, Manabu Sotomatsu, Hirokazu Arakawa, Keizo Horibe, Myoung-Ja PARK, Takashi Taga, Souichi Adachi, Akio Tawa, Satoru Miyano, Seishi Ogawa, Yasuhide Hayashi
Journal: Blood (2015)
Identification of New Leukemia Associated Gene Mutations by Whole Genome Sequencing of DNA From Two Siblings with Congenital Neutropenia and Secondary AML
Authors: Maksim Klimiankou, Siarhei Kandabarau, Marlene Reuter, Anna-Lena Hagemann, Cornelia Zeidler, Karl Welte, Julia Skokowa
Journal: Blood (2012)
The Brain Transcription Factor OTX1 Is Activated in Specific Non-Hodgkin Lymphoma Subtypes and Normally Expressed in a Germinal Center-Restricted Small Subpopulation of CD138+ Plasmacell-Like Cells.
Authors: Filippo Russo, Daniela Omodei, Dario Acampora, Rosaria De Filippi, Valeria Severino, Raffaele Di Francia, Ferdinando Frigeri, Pietro Mancuso, Anna De Chiara, Renato Franco, Stefano Casola, Antonio Pinto, Antonio Simeone
Journal: Blood (2007)
THU0349 Early Symptoms of Systemic Lupus Erythematosus (SLE) Recalled by 337 SLE Patients: Table 1.
Authors: N. Leuchten, B. Milke, B. Winkler-Rohlfing, D. Daikh, T. Dörner, S. Johnson, M. Aringer
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> EULAR and ACR have jointly funded a project to develop systemic lupus erythematosus (SLE) classification criteria, aiming at earlier and more accurate classification of the disease. This abstract reports on an early phase of that project, aimed at collecting potential candidate criteria. Since SLE patients usually experience the onset and diagnosis as a critical life event, memories of this time appear remarkably accurate. <h3>Objectives</h3> The objective of this study was to identify early symptoms of SLE from the patient perspective. <h3>Methods</h3> As approved by the local ethics committee, we conducted a cross-sectional survey of German SLE patients. An anonymous self-report questionnaire was published in the "Schmetterling" the quarterly journal of the "Lupus erythematodes Selbsthilfegemeinschaft", the German SLE patient association. Patients were asked for year of and age at their initial diagnosis. The questionnaire included typical organ manifestations, symptoms and autoantibodies. In addition, patients were asked to add additional symptoms in free text. For each symptom, boxes were provided to indicate the presence of the symptom before diagnosis, in the first year of diagnosis and at the time of completion of the questionnaire. <h3>Results</h3> 333 patient questionnaires were completed and mailed. Of the respondents, 93% were female. The respondents9 mean age at diagnosis was 36 years, their mean disease duration was 17 years. 83% reported to be definitely ANA-positive. Joint, skin and kidney involvement were reported at 82%, 66% and 33%, respectively. 22% of patients reported fibromyalgia. For the time before and shortly after diagnosis, more than 50% of the patients reported fatigue (89%), joint pain (87%), sensitivity to sunlight (79%), myalgias (76%), rash (71%), fever (54%), Raynaud9s (52%) and hair loss (51%). Approximately one third (37%) affirmed shortness of breath. Free text symptoms reported frequently before or early in diagnosis are listed in Table 1. <h3>Conclusions</h3> For a Caucasian European SLE patient population, the overall characteristics suggested meaningful representation. While many symptoms were reported as expected, a significant number of patients volunteered gastrointestinal complaints and symptoms of the central and peripheral nervous system. Solicitation of self reported information from the patient perspective has not been widely used in the development of classification criteria for SLE. These data add to the information on early SLE symptoms that may help improve classification of early SLE. <h3>Disclosure of Interest</h3> None declared
Polymorphisms in the Human Organic Cation Transporter (hOCT1) (Solute Carrier Family 22, SLC22A1) and the Multidrug Resistance Gene (MDR1, ABCB1): Correlation with Imatinib Levels and Clinical Course in Chronic Myeloid Leukemia Patients
Authors: Jacob Vine, Sara Bar Cohen, Rosa Ruchlemer, Neta Goldschmidt, Moshe Levin, Diana Libster, Alexander Gural, Moshe E. Gatt, David Lavie, Dina Ben-Yehuda, Deborah Rund
Journal: Blood (2012)
Early Lymphocyte Recovery after Autologous Stem Cell Transplantation Predicts Superior Survival in Mantle Cell Lymphoma.
Authors: Cristina Joao, Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N.M. Micallef, Patrick B. Johnston, Dennis A. Gastineau, Svetomir N. Markovic
Journal: Blood (2005)
IL-21 Plus CpG ODN Induces Granzyme B-Dependent Induction of Apoptosis in CD5-Positive B Cells Including B-CLL Cells.
Authors: Sue E. Blackwell, Bernd Jahrsdoerfer, James E. Wooldridge, Jian Huang, Melinda W. Andreski, Laura S. Jacobus, Christiana M. Taylor, George J. Weiner
Journal: Blood (2006)
Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines.
Authors: Alfonso Quintas-Cardama, Weigang Tong, Taghi Manshouri, Jan Cools, D. Gary Gilliland, Hagop M. Kantarjian, Jorge Cortes, Guillermo Garcia-Manero
Journal: Blood (2006)
OC-053 Lectin-Based Near infra-red Molecular Imaging for Dysplasia Detection in Barrett’s Oesophagus: An ex-vivo Study on Human Tissue
Authors: M Di Pietro, A Neves, M O’Donovan, D Waterhouse, S Bohndiek, K Brindle, RC Fitzgerald
Journal: Gut (2016)

<h3>Introduction</h3> Detection of early neoplasia in Barrett’s oesophagus (BO) by white-light endoscopy is challenging due to the inconspicuous nature of dysplasia. Molecular imaging using fluorescently labelled wheat-germ agglutinin (WGA) is a promising tool as this topically applied imaging agent shows lower binding to dysplastic versus non-dysplastic BO.<sup>1</sup> However in an endoscopy setting, the detection of fluorescence in the blue/green range is limited by high-levels of tissue autofluorescence. This limitation can be overcome by using near infra-red (NIR) imaging. We aimed to assess in an <i>ex-vivo</i> model the feasibility of WGA-based NIR imaging for detection of dysplasia in BO. <h3>Methods</h3> we recruited patients with early BO-related neoplasia undergoing endoscopic mucosal resection (EMR). Freshly collected EMR specimens were sprayed with WGA-IR800CW and then imaged with a high-sensitivity NIR camera. Fluorescence images were captured and up to two punch biopsies were collected from each EMR under fluorescence guidance. The EMRs were paraffin embedded, cut every 2 mm and processed for histopathological assessment. Each section was scored by an expert GI pathologist every 1 mm to construct a pathology grid, which was manually co-registered with the fluorescence image. The mean fluorescence intensity (MFI) of cells in dysplastic and non-dysplastic areas was compared by the Wilcoxon matched-pairs signed rank test. Only EMR specimens with at least one dysplastic gland were included in the analysis. In addition, the MFI of punch biopsies taken from dysplastic and non-dysplastic areas was also compared by Mann-Whitney test. <h3>Results</h3> Ten patients were recruited at a single centre. A total of 18 EMR specimens and 33 punch biopsies were collected, of which 10 were dysplastic. In the whole EMR analysis, we found a significantly lower MFI for dysplastic versus non-dysplastic areas (P = 0.0012), in accordance with the reported reduced binding of WGA to neoplastic BO epithelium. Similarly, we found a nearly 2 fold reduction in the MFI of punch biopsies taken from dysplastic as compared to non-dysplastic (ND) areas (P = 0.0002) (Figure 1). <h3>Conclusion</h3> WGA-based NIR imaging is an effective method for differentiating dysplastic from non-dysplastic BO mucosa <i>ex vivo</i>, which reduces the effects of tissue autofluorescence. <i>In-vivo</i> studies are now required to test the efficacy of this method for detecting dysplasia during endoscopic surveillance. <h3>Reference</h3> 1 Bird-Lieberman, <i>et al</i>. <i>Nat Med</i> 2012. <h3>Disclosure of Interest</h3> None Declared
FRI0185 Are There Differences in Baseline Characteristics of Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors According To The Presence of Comorbidities?: Table 1
Authors: M.V. Hernández, C.A. Sánchez-Piedra, J.A. Gόmez-Puerta, F. Sánchez-Alonso, J. Manero-Ruiz, E. Cuende, R. Rosello Pardo, E. Perez-Pampin, C. Rodriguez-Lozano, R. Sanmartí, J.J. Gόmez-Reino
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is often associated with comorbidities that may affect the therapeutic choice or a different management in clinical practice. It is unclear whether patients with comorbidities have a different profile from those without <h3>Objectives</h3> To analyze differences in the baseline characteristics of RA patients treated with tumor necrosis factor inhibitors (TNFi) according to the presence or not of concomitant comorbidities <h3>Methods</h3> All patients from the BIOBADASER 2.0 register with a diagnosis of RA treated with TNFi from January 2008 to December 2014 were selected and divided into 2 groups according to the presence or not of comorbidities. Comorbidity was defined as ≥1 of the following at initiation of TNFi: ischemic heart disease; malignancy; diabetes; chronic pulmonary obstructive disease; smoking; hypercholesterolemia; hypertension; heart failure; renal failure; osteoporosis; Epstein Barr, hepatitis B or C virus infection; and others. Variables analyzed were: age; gender; disease duration; disease activity at initiation of biological therapy measured by the DAS-28 score; number of previous biological agents (0, 1, ≥2); concomitant glucocorticoids or synthetic DMARD; and biological duration. Differences between groups were analyzed <h3>Results</h3> From January 2008 to December 2014, 640 RA treated with TNFi were included in the BIOBADASER 2.0 register. Baseline characteristics are shown in Table 1. Patients with associated comorbidities were significantly older, less frequently female, had received a higher number of previous biologics, and had a higher baseline DAS-28 compared with patients without comorbidities <h3>Conclusions</h3> RA patients treated with TNFi with baseline comorbidities are significantly older, have a higher baseline DAS 28 and had received more previous biologics, suggesting a RA population with higher activity than those without comorbidities. Whether this higher baseline activity favors the development of comorbidities, or whether comorbidities limited therapy in these patients, requires analysis. <h3>Disclosure of Interest</h3> None declared
Alternate Splicing Factor Fox2 Affects Growth and Survival of Multiple Myeloma Cells
Authors: Weihua Song, Yiguo Hu, Guang Yang, Parantu K Shah, Weisong Shan, Yu-Tzu Tai, Yi Li, Stephane Minvielle, Hervé Avet-Loiseau, Kenneth C. Anderson, Cheng Li, Nikhil C. Munshi
Journal: Blood (2011)
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.
Authors: F. Morschhauser, D. Huglo, G. Martinelli, G. Paganelli, P.L. Zinzani, D. Hadjiyiannakis, A. Liberati, T. Illidge, N. Milpied, H. Stein, J. Kalmus, P. Morel, U. Reimann, R. Marcus
Journal: Blood (2004)
BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)
Authors: Barbarella Lucarelli, Pietro Merli, Alice Bertaina, Matilde Sinibaldi, Stefania Gaspari, Luisa Strocchio, Angela Pitisci, Giuseppina Li Pira, Giuseppe Maria Milano, Annemarie Moseley, Concetta Quintarelli, Franco Locatelli
Journal: Blood (2015)
Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection.
Authors: Peter Kim, Gitte Gerhard, Troy O. Harasym, Wahseng Lim, Natalia Zisman, Lawrence D Mayer, Donna E. Hogge
Journal: Blood (2009)
Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.
Authors: Mitchell Horwitz, David Rizzieri, Gwynn D. Long, Cristina Gasparetto, Ashley Morris, Keith Sullivan, John Chute, Dawn Marshall, Nelson Chao
Journal: Blood (2006)
Disruption of EPCR-Dependent Functions By Plasmodium Falciparum Erythrocyte Membrane Protein 1 (PfEMP1) Can be Rescued By a Soluble EPCR Variant
Authors: Jens E.V. Petersen, Eveline A. Bouwens, Ibai Tamayo, Louis Turner, Christian Wang, Monique Stins, Thor G. Theander, José Hermida, Thomas Lavstsen, Laurent O. Mosnier
Journal: Blood (2014)